Ernexa Therapeutics Inc. (ERNAW) Return on equity 2016–2025
Ernexa Therapeutics Inc. (ERNAW) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-828.0%FY2025 · since FY2016: -76.0% → -828.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -828.0% | +1166.6 pp |
| FY2024 | -1994.6% | -1815.6 pp |
| FY2023 | -179.0% | — |
| FY2021 | -1600.0% | -1525.2 pp |
| FY2020 | -74.8% | -45.2 pp |
| FY2019 | -29.6% | -24.9 pp |
| FY2018 | -4.7% | +21.8 pp |
| FY2017 | -26.5% | +49.5 pp |
| FY2016 | -76.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice